Clinical Trials - The company is on track to report data from the MYTHIC dose expansion clinical trial in December 2024, with plans to begin a registrational trial in 2025[1] - The first patient has been dosed in the Phase 1 POLAR trial evaluating RP-3467, a Polq ATPase inhibitor, alone and in combination with the PARP inhibitor, olaparib[1] - The company presented positive updated safety and tolerability data from the Phase 1 MYTHIC trial, showing a reduction in Grade 3 anemia to 22.6% from 51.4%[4] Financial Performance - Cash, cash equivalents, and marketable securities as of September 30, 2024, were $179.4 million, sufficient to fund operations into the second half of 2026[11] - Revenue from collaboration agreements was nil for the three months ended September 30, 2024, compared to $2.2 million for the same period in 2023[12] - Net R&D expenses were $28.4 million for the three months ended September 30, 2024, down from $32.7 million for the same period in 2023[13] - General and administrative expenses were $6.4 million for the three months ended September 30, 2024, compared to $7.9 million for the same period in 2023[14] - The net loss for the three months ended September 30, 2024, was $34.4 million, or $0.81 per share, compared to a net loss of $18.9 million, or $0.45 per share, for the same period in 2023[15] - Total operating expenses for Q3 2024 were $36,372,000, down from $40,577,000 in Q3 2023, a decrease of 5.4%[20] - Net loss for Q3 2024 was $34,406,000, compared to a net loss of $18,879,000 in Q3 2023, an increase of 82.7%[20] - Research and development expenses for the nine months ended September 2024 were $91,446,000, down from $98,327,000 for the same period in 2023, a decrease of 7%[20] - General and administrative expenses for Q3 2024 were $6,444,000, a decrease of 18.1% from $7,868,000 in Q3 2023[20] - Interest income for Q3 2024 was $2,512,000, compared to $3,312,000 in Q3 2023, a decrease of 24.1%[20] - Comprehensive loss for Q3 2024 was $34,132,000, compared to $18,707,000 in Q3 2023, an increase of 82.5%[20] - Net loss per share attributable to common shareholders for Q3 2024 was $(0.81), compared to $(0.45) in Q3 2023, a decrease of 80%[20] - Total other income for Q3 2024 was $2,451,000, down from $3,240,000 in Q3 2023, a decrease of 24.4%[20] - Restructuring expenses for Q3 2024 were $1,527,000, with no restructuring expenses reported in Q3 2023[20] Workforce and Strategic Changes - The company reduced its overall workforce by approximately 25% as part of a strategic reprioritization of its R&D activities[10] - Total assets as of September 30, 2024, were $206.4 million, down from $253.9 million as of December 31, 2023[19]

Core Insights - Repare Therapeutics (RPTX) shares increased by 8% following the announcement of dosing the first patient in an early-stage study for the combination of RP-3467 and AstraZeneca's Lynparza to treat advanced solid tumors [1] - The combination of RP-3467 and Lynparza has shown promising preclinical results, leading to complete and durable tumor regressions without additional toxicities, indicating potential to improve patient outcomes by addressing PARP inhibitor resistance [2] - The ongoing phase I POLAR study aims to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of RP-3467, targeting 52 patients with specific advanced solid tumors [3][4] Company Pipeline - Repare utilizes its CRISPR-enabled SNIPRx platform to develop targeted cancer therapies focusing on genomic instability and DNA damage repair [5] - The company is also evaluating lunresertib, a PKMYT1 inhibitor, in combination with camonsertib, an ATR inhibitor, in a phase I study for ovarian and endometrial cancer, with top-line data expected soon [6] - RP-1664, an oral PLK4 inhibitor, is currently in a phase I study for advanced solid tumors, indicating a diverse clinical-stage pipeline [7] Market Context - Year to date, RPTX shares have decreased by 53.6%, contrasting with a 2% decline in the broader industry [3] - Repare currently holds a Zacks Rank 3 (Hold), while ANI Pharmaceuticals and Alnylam Pharmaceuticals are ranked 1 (Strong Buy) [8]

and the first to the state of the state of the state of the states of the states of the station of the states of the states of the station of the state of the state of the te I 0 I Image Source Repare Therapeutics Inc. (NASDAQ:RPTX) is gearing up to report results from its phase 1 MYTHIC trial, which is using lunresertib [RP-6306] in combination with camonsertib [RP-3500] for the treatment of patients with platinum-resistant ovarian and endometrial cancers. This will be a major inflection point because it w ...

Repare Therapeutics Inc. (RPTX) came out with a quarterly loss of $0.82 per share versus the Zacks Consensus Estimate of a loss of $0.85. This compares to loss of $0.28 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 3.53%. A quarter ago, it was expected that this company would post a loss of $0.10 per share when it actually produced earnings of $0.30, delivering a surprise of 400%. Over the last four quarters, the company ha ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________ to ___________________ | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |--------------------------------- ...

Exhibit 99.1 Repare Therapeutics Provides Business and Clinical Update and Reports Second Quarter 2024 Financial Results Reiterated guidance on data readout from MYTHIC trial evaluating lunresertib and camonsertib in patients with platinum-resistant ovarian and endometrial cancers in Q4 2024 Granted Fast Track designation by the FDA for lunresertib in combination with camonsertib in platinum-resistant ovarian cancer Presented positive initial data from Phase 1 MINOTAUR clinical trial evaluating lunresertib ...

ANVS beat estimates in three of the trailing four quarters and missed once, delivering an average negative surprise of 1.39%. In the past 30 days, the Zacks Consensus Estimate for Compugen's 2024 earnings per share has increased from 2 cents to 5 cents. The consensus estimate for 2025 loss per share is currently pegged at 11 cents. Year to date, shares of CGEN have gained 5.6%. CGEN's earnings beat estimates in three of the trailing four quarters and missed once, delivering an average surprise of 5.79%. In ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 Repare Therapeutics Inc. (Exact Name of Registrant as Specified in its Charter) Québec Not applicable (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) St-Laurent, Québec, Canada H4S 1Z9 (Address of principal executive offices) (Zip Co ...

Exhibit 99.1 Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2024 Financial Results Phase 1 MYTHIC clinical trial of lunresertib in combination with camonsertib demonstrated a significant reduction in Grade 3 anemia and continued trends of patient response and benefit; FDA agrees with RP2D First patient dosed in Phase 1 MYTHIC clinical trial of lunresertib in combination with the WEE1 inhibitor, Debio 0123; first clinical trial inhibiting both PKMYT1 and WEE1 Initiating P ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39335 Repare Therapeutics Inc. (Exact name of Registrant as specified in its Charter) Québec Not applicable (State or other jurisdict ...